Vanke A: the contract sales amount in May was 30.76 billion yuan

CCRC In China: A Rosy Picture for a Silver Future, but Still a Greenhorn Venture

The model of elderly care service represented by the United States, the Continuing Care Retirement Community (CCRC), is gradually attracting attention in China.

Kanghong’s Conbercept Receives Marketing Authorization in Guyana

Kanghong Pharmaceutical (康弘药业) said its subsidiary Kanghong Bioscience had received a drug registration certificate from Guyana’s Food and Drug Department for conbercept ophthalmic injection, marketed under the brand name Lumitin (朗沐).

Wantai BioPharm’s Nine-Valent HPV Vaccine Wins First Overseas Approval in Thailand

Wantai BioPharm (万泰生物) announced on Aug. 11 that the nine-valent HPV vaccine developed by its wholly owned subsidiary, Xiamen Innovax Biotech (万泰沧海), has received marketing authorization from Thailand’s Food and Drug Administration. The approval marks the vaccine’s first clearance outside China and an important step in Wantai BioPharm’s international expansion.

Alphamab Licenses Cancer Drug to Pathos AI in Deal Worth More Than US$2.2 Billion

Alphamab Oncology (康宁杰瑞生物制药) has licensed the overseas rights to its experimental cancer drug JSKN016 to US-based Pathos AI in a deal potentially worth more than US$2.2 billion, marking another major overseas licensing agreement for China’s rapidly expanding innovative-drug sector.

Vanke Property Services Unit Aims A Billion-USD IPO

Onewo, formerly known as Vanke Service, was once the property service department of Vanke. The company’s earliest official announcement that it would split Onewo to go public was in 2021.